Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Purdue Pharma L.P. v. Epic Pharma, LLC, No. 14-1294 (Fed. Cir. Feb. 1, 2016)

Affirmed
Invalidity (§ 102/§ 103) Motion to Dismiss
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 14-1294
Also Docketed
No. 14-1296, No. 14-1306, No. 14-1307, No. 14-1311, No. 14-1312, No. 14-1313, No. 14-1314 (consolidated; same document)
Decided
February 1, 2016
Judge
Prost, C.J.
Document
Precedential Opinion
Length
27 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This appeal arises from consolidated Hatch -Waxman proceedings involving the reformulated version of the pain reliever OxyContin®. The Appellants, Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., and Rhodes Technologies (collectively, “Purdue”) and Grunenthal GmbH (“Grunenthal”) asserted a number of claims from multiple different patents against the Appe l- ∗ Honorable Leonard P. Stark, Chief District Judge, United States District Court for the District of Delaware, sitting by designation. PURDUE PHARMA L.P. v.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error